Alivus Life Sciences Reports Q1 Results: Total Income Reaches 6,628.15 Million
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its unaudited financial results for the first quarter ended June 30, 2026. The results reflect the company's operational performance across key income and expense categories.The company reported a revenue from operations of 6,404.14 million in the current quarter (Q1 FY2027), while total income stood at 6,628.15 million. This compares against 6,018.46 million recorded during the same period in the previous year (Q1 FY2026).
The unaudited financial results for the quarter ended June 30, 2026, are detailed below:
| Particulars | Quarter Ended June 30, 2026 (Unaudited) | March 31, 2026 (Refer No 7) | June 30, 2025 (Unaudited) | March 31, 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 6,404.14 million | 6,891.17 million | 6,018.46 million | 25,518.32 million |
| Other income | 224.01 million | 227.78 million | 89.85 million | 604.11 million |
| Total income | 6,628.15 million | 7,118.95 million | 6,108.31 million | 26,122.43 million |
| Total expenses | 4,505.92 million | 4,960.96 million | 4,478.50 million | 18,352.77 million |
| Profit before tax | 2,122.23 million | 2,157.99 million | 1,629.81 million | 7,513.09 million |
| Total tax expenses | 521.47 million | 531.38 million | 414.46 million | 1,868.26 million |
| Net profit for the period | 1,600.76 million | 1,626.61 million | 1,215.35 million | 5,644.83 million |
Capital Structure and Operational Insights
The company confirmed that it operates in the Active Pharmaceutical Ingredient (API) segment as its sole reporting segment based on the information reviewed by the Chief Operating Decision Maker (CODM).Regarding financial structure, the paid up equity share capital increased to 245.48 million upon the allotment of 3,100 equity shares at a face value of Rs. 2 each, pursuant to the Employee Stock Option Scheme, 2021 during the quarter ended June 30, 2026.
The results for the financial year ending March 31, 2026, included exceptional items relating to the application of new labour codes, comprising gratuity amounting to Rs. 170.02 million and compensated absences amounting to Rs. 86.55 million, recognized as past service cost.
The company also noted that there were 542,531 options outstanding as of June 30, 2026, under the Employee Stock Option Plan 2021.
ALIVUS Stock Price Movement
Today, shares of Alivus Life Sciences Limited shed 0.41% to settle at ₹1095.7 after closing trading. The equity navigated a range between a low of ₹1089.8 and a high of ₹1142.9, with 53,239 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.